首页> 外文OA文献 >Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience.

【2h】

Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience.

机译：Raltegravir，maraviroc，etravirine：一种有效的蛋白酶抑制剂和核苷类逆转录酶抑制剂保留方案，用于三级经验的HIV感染患者的挽救治疗。

页面导航

著录项
相似文献
相关主题

著录项

作者
Nozza S; Galli L; Visco F; Soria A; Canducci F; Salpietro S; Gianotti N; Bigoloni A; Torre LD; Tambussi G; Lazzarin A; Castagna A;
展开▼
作者单位

展开▼
年度 2010
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. [J] . Nozza S, Galli L, Visco F, AIDS . 2010,第6期

机译：Raltegravir，maraviroc，etravirine：一种有效的蛋白酶抑制剂和核苷逆转录酶抑制剂节约方案，可用于具有三级经验的HIV感染患者的抢救治疗。
2. Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection. [J] . Haubrich RH, Riddler SA, Ribaudo H, AIDS . 2011,第18期

机译：初步病毒衰减，以评估蛋白酶抑制剂保存，非核苷逆转录酶抑制剂保存和核苷逆转录酶抑制剂保存方案对HIV感染的一线治疗的相对抗逆转录病毒效力。
3. A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients. [J] . Harris M, Cote H, Ochoa C JAIDS: Journal of acquired immune deficiency syndromes . 2009,第3期

机译：一项针对抗逆转录病毒初治HIV感染患者的核苷类似物逆转录酶抑制剂保护方案的随机，开放标签研究。
4. Dyslipidemia among HIV-infected tuberculosis patients taking once-daily non-nucleoside reverse transcriptase inhibitor based antiretroviral therapy in India. [D] . Chandrasekaran, Padmapriyadarsini. 2010

机译：在印度，每天接受一次基于非核苷类逆转录酶抑制剂的抗逆转录病毒疗法的HIV感染结核病患者的血脂异常。
5. Second-line protease inhibitor-based highly active antiretroviral therapy after failing non-nucleoside reverse transcriptase inhibitors-based regimens in Asian HIV-infected children [O] . Torsak Bunupuradah, Thanyawee Puthanakit, Paul Fahey, -1

机译：基于二线蛋白酶的抑制剂的高活性抗逆转录病毒治疗在亚洲艾滋病毒感染儿童的基于非核苷逆转录酶抑制剂的基于中的方案
6. Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study [O] . Nozza S., Galli L., Antinori A., 2015

机译：每天150 mg的Maraviroc加上洛匹那韦/利托那韦，一种用于HIV感染天真的患者的核苷/核苷酸逆转录酶抑制剂保护方案：VEMAN研究的48周最终结果

Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience.

著录项

相似文献

相关主题

期刊订阅